Artificial intelligence in the prediction of protein–ligand interactions: recent advances and future directions
Abstract New drug production, from target identification to marketing approval, takes over 12 years and can cost around $2.6 billion. Furthermore, the COVID-19 pandemic has unveiled the urgent need for more powerful computational methods for drug discovery. Here, we review the computational approach...
Saved in:
Published in | Briefings in bioinformatics Vol. 23; no. 1 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
17.01.2022
Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract
New drug production, from target identification to marketing approval, takes over 12 years and can cost around $2.6 billion. Furthermore, the COVID-19 pandemic has unveiled the urgent need for more powerful computational methods for drug discovery. Here, we review the computational approaches to predicting protein–ligand interactions in the context of drug discovery, focusing on methods using artificial intelligence (AI). We begin with a brief introduction to proteins (targets), ligands (e.g. drugs) and their interactions for nonexperts. Next, we review databases that are commonly used in the domain of protein–ligand interactions. Finally, we survey and analyze the machine learning (ML) approaches implemented to predict protein–ligand binding sites, ligand-binding affinity and binding pose (conformation) including both classical ML algorithms and recent deep learning methods. After exploring the correlation between these three aspects of protein–ligand interaction, it has been proposed that they should be studied in unison. We anticipate that our review will aid exploration and development of more accurate ML-based prediction strategies for studying protein–ligand interactions. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 National Science Foundation (NSF) USDOE Advanced Research Projects Agency - Energy (ARPA-E) National Institutes of Health (NIH) AR0001213; SC0020400; SC0021303; DBI1759934; IIS1763246; R01GM093123 USDOE Office of Science (SC), Biological and Environmental Research (BER) |
ISSN: | 1467-5463 1477-4054 1477-4054 |
DOI: | 10.1093/bib/bbab476 |